Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Tactile Systems Technology (NASDAQ:TCMD) is the #1 top healthcare stock out of 1091 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Tactile Systems Technology (NASDAQ:TCMD) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: C, Financials: A, and AI: C.

Tactile Systems Technology (NASDAQ:TCMD) has a Due Diligence Score of 45, which is 19 points higher than the healthcare sector average of 26. It passed 14 out of 33 due diligence checks and has strong fundamentals. Tactile Systems Technology has seen its stock return 53.45% over the past year, overperforming other healthcare stocks by 83 percentage points.

Tactile Systems Technology has an average 1 year price target of $23.25, a downside of -16.43% from Tactile Systems Technology's current stock price of $27.82.

Tactile Systems Technology stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Tactile Systems Technology, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the #2 top healthcare stock out of 1091 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ironwood Pharmaceuticals (NASDAQ:IRWD) is: Value: A, Growth: B, Momentum: B, Sentiment: C, Safety: C, Financials: A, and AI: A.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a Due Diligence Score of 35, which is 9 points higher than the healthcare sector average of 26. It passed 11 out of 33 due diligence checks and has average fundamentals. Ironwood Pharmaceuticals has seen its stock return 0.56% over the past year, overperforming other healthcare stocks by 30 percentage points.

Ironwood Pharmaceuticals has an average 1 year price target of $3.00, a downside of -16.2% from Ironwood Pharmaceuticals's current stock price of $3.58.

Ironwood Pharmaceuticals stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Ironwood Pharmaceuticals, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Collegium Pharmaceutical (NASDAQ:COLL) is the #3 top healthcare stock out of 1091 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Collegium Pharmaceutical (NASDAQ:COLL) is: Value: A, Growth: B, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: A.

Collegium Pharmaceutical (NASDAQ:COLL) has a Due Diligence Score of 49, which is 23 points higher than the healthcare sector average of 26. It passed 17 out of 33 due diligence checks and has strong fundamentals. Collegium Pharmaceutical has seen its stock return 61.62% over the past year, overperforming other healthcare stocks by 91 percentage points.

Collegium Pharmaceutical has an average 1 year price target of $49.50, an upside of 1.79% from Collegium Pharmaceutical's current stock price of $48.63.

Collegium Pharmaceutical stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Collegium Pharmaceutical, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 70 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 12.13%, which is 10 percentage points higher than the healthcare sector average of 1.84%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 9.39%, which is 8 percentage points higher than the healthcare sector average of 1.84%. Spok Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 154.3% indicates that its high dividend yield might not be sustainable for the long-term.

Embecta (NASDAQ:EMBC) has an annual dividend yield of 5.08%, which is 3 percentage points higher than the healthcare sector average of 1.84%.

Embecta's dividend payout ratio of 36.6% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -0.44% in the last day, and down -0.02% over the last week. Sonnet Biotherapeutics Holdings was the among the top losers in the healthcare sector, dropping -59.35% yesterday.

Sonnet BioTherapeutics Holdings shares are trading lower after the company announced its stockholders approved a business combination with Hyperliquid Strategies and Rorschach I.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Organon & Co (NYSE:OGN) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -53.29% in the past year. It has underperformed other stocks in the healthcare sector by -23 percentage points.

Bausch Health Companies (NYSE:BHC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Bausch Health Companies's stock has dropped -10.71% in the past year. It has overperformed other stocks in the healthcare sector by 19 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 27.15% in the past year. It has overperformed other stocks in the healthcare sector by 57 percentage points.

55.36% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 27% over the next year.

7.58% of healthcare stocks have a Zen Rating of A (Strong Buy), 11.09% of healthcare stocks are rated B (Buy), 48.07% are rated C (Hold), 24.39% are rated D (Sell), and 8.87% are rated F (Strong Sell).